Therapeutics News and Research

RSS

Nanoparticle antimicrobial gel formulation for topical use

Scientists in India are reporting successful laboratory tests of a new and potentially safer alternative to silver-based gels applied to the skin of burn patients to treat infections.

26 Jul 2009

Parabon NanoLabs awarded research grant to develop novel cancer therapeutics

Parabon NanoLabs, a leading designer and manufacturer of breakthrough products at the nanoscale, announced today its award of a National Science Foundation (NSF) Small Business Innovative Research (SBIR) grant.

21 Jul 2009

Targeted nanoparticles boost arsenic’s anticancer punch

Arsenic trioxide has a long history as a potent human poison, but it also has proven valuable as one of the primary treatment options for acute promyelocytic leukemia. Efforts to use arsenic trioxide to treat other types of cancer are under way, but clinical trials are revealing that the extreme toxicity of this material is likely to limit its utility as a broad-spectrum anticancer agent.

21 Jul 2009

Researchers decipher special role of the messenger Beta-interferon for immune responses

Researchers from the Molecular Immunology group at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany have now shown that Beta-Interferon also plays a crucial role during an immune response: without Beta-Interferon immune cells are unable to show "wanted posters" of pathogens to other cells.

20 Jul 2009

New discovery on DNA repair mechanism

Researchers at Washington University School of Medicine in St. Louis have shed new light on a process that fixes breaks in the genetic material of the body's cells. Their findings could lead to ways of enhancing chemotherapy drugs that destroy cancer cells by damaging their DNA.

17 Jul 2009

New drug blocks common cancer pathway

Scientists have developed a new drug which can reduce the growth of tumours in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics ** this week.

15 Jul 2009

Skin cancer researchers throw new light on tumour growth

Three researchers from the Dermatology Research Foundation at the University of Sydney have identified a compound produced by certain fatal skin cancer tumours, providing new hope for developing treatments.

14 Jul 2009

Researchers profile genes in acutely ill idiopathic pulmonary fibrosis patients

The first findings from a one-of-a-kind, patient-driven effort to provide lung tissue for research might help doctors predict when patients with idiopathic pulmonary fibrosis (IPF) are becoming dangerously ill and also could point the way to interventions that could sustain them until life-saving transplants can be performed.

7 Jul 2009

Specialized glycans act as tumor suppressors

Scientists at Burnham Institute for Medical Research (Burnham) have discovered that specialized complex sugar molecules (glycans) that anchor cells into place act as tumor suppressors in breast and prostate cancers.

6 Jul 2009

Computer-guided nanoparticle therapy destroys tumors

Gold nanoshells are among the most promising new nanoscale therapeutics being developed to kill tumors, acting as antennas that turn light energy into heat that cooks cancer to death. Now, a multi-institutional research team has shown that polymer-coated gold nanorods one-up their spherical counterparts, with a single dose completely destroying all tumors in a nonhuman animal model of human cancer.

28 Jun 2009

New tuberculosis drug targets

A fundamental question about how sugar units are strung together into long carbohydrate chains has also pinpointed a promising way to target new medicines against tuberculosis.

23 Jun 2009

Goby fish may bring new drugs for high blood pressure

Medical scientists at the University of Leicester are investigating how a species of fish from the Pacific Ocean could help provide answers to tackling chronic conditions such as hereditary high blood pressure and kidney disease.

22 Jun 2009

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise

Antisense Therapeutics Ltd. (ASX: ANP) has reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes.

18 Jun 2009

Circadian Technologies granted significant European patent

Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.

17 Jun 2009

Discovery in dendritic cell signalling pathways pave way for new therapeutic targets

Scientists from A*STAR's Singapore Immunology Network (SIgN) and the University of Milano-Bicocca, Italy, have discovered another signaling pathway for the activation and apoptosis, or programmed cell death, of dendritic cells. This discovery was published in the advanced online publication of Nature on 15 Jun 2009.

15 Jun 2009

Scientists gain new insights into the genetic susceptibility of multiple sclerosis

Australian and New Zealand researchers have accelerated research into Multiple Sclerosis by discovering two new locations of genes which will help to unravel the causes of MS and other autoimmune disease.

15 Jun 2009

Single gene found to control growth of some cancers

Research led by Ashok Aiyar, PhD, Associate Professor of Microbiology at LSU Health Sciences Center New Orleans, showing that a single gene can control growth in cancers related to the Epstein-Barr virus and that existing therapeutics can inactivate it, will be published in the June 12, 2009 online issue of PLoS Pathogens.

15 Jun 2009

Innovative partnership targets cancer-causing 'chaperones'

Cancer Research Technology (CRT) and The Institute of Cancer Research (ICR) today announced a major research collaboration with AstraZeneca. The three partners will combine their expertise to discover and develop potential new anti-cancer drugs to target molecular "chaperones" which support the growth of cancer cells.

10 Jun 2009

New understanding of structure of bacteria responsible for traveler's diarrhea

Researchers at Boston University School of Medicine (BUSM), the Naval Medical Research Center and the National Institutes of Health, have solved the structure of thin hair-like fibers called "pili" or "fimbriae" on the surface of bacteria that cause traveler's diarrhea.

9 Jun 2009

New lung cancer therapy with vaporized viral vector shows promise

A new lung cancer therapy employing a vaporized viral vector to deliver a cancer-inhibiting molecule directly to lung tissue shows early promise in mouse trials, according to researchers at the Ministry of Education, Science and Technology in Korea.

9 Jun 2009